Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
Status:
RECRUITING
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
To study the optimal therapeutic strategies for salvage treatment of refractory/relapsed AML, and to clarify the effectiveness and safety of various salvage treatment options. A prospective, multicenter, platform-type study was conducted to explore the overall response rate, tolerability, and survival of patients with R/R AML with different treatment regimens.
Phase:
NA
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China